Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Foresight Diagnostics Founders Respond to Roche Lawsuit, Says Claims Asserted in Bad Faith
Foresight said that Roche's asserted trade secrets were not secret and that the technologies at the heart of the claim are fundamentally different.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
The San Jose, California-based company has developed AccuScan, which analyzes a patient's circulating tumor DNA but does not require bespoke reagents.
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.